We are excited to announce a new project that changes the way we analyze miRNA-122. This small non-coding RNA is known as a biomarker for liver injury. With the support of the 2022 ICEX-Invest in Spain’s funding program, we are implementing the unique PCR-Free testing of miRNA-122 using DESTINA’s ChemiRNATM Tech reagents merged with AVAC Mecwins platform.
DESTINA and Mecwins are partnering to develop a new alliance to compete in the molecular and immunoassay market. The partnership aims to eliminate false positives and negatives in diagnostic tests, and accelerate the availability of DESTINA’s services in Granada. The objectives include consolidating DESTINA’s presence in Spain, achieving superior specificity and sensitivity in DESTINA tests with the AVAC Analyzer, and securing additional funding through venture capital or institutional investors.